SAN CARLOS, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, will report its second quarter and first half 2024 financial results on Thursday, August 8, 2024. Management will host a conference call and live audio webcast to discuss these results and provide a corporate update at 4:30 p.m. ET. To listen to the ...

文章核心观点 - 美国投资银行Piper Sandler下调了Iovance Biotherapeutics Inc(IOVA)的评级,原因是该公司的处方药Amtagvi(lifileucel)上市缓慢 [1] - Amtagvi是一种用于治疗无法手术切除或转移至身体其他部位的恶性黑色素瘤的个体化T细胞疗法,于2月获得FDA批准 [1] - 尽管有大量患者登记使用Amtagvi,但实际使用率很低,仅有5-6名患者在2024年第二季度接受输注(13%的使用率) [3] - 主要挑战在于治疗时间过长,患者可能需要等待6周才能获得制造时间 [4] 公司相关 - Piper Sandler下调了2024年第二季度Amtagvi收入预估,从原先的24亿美元降至12亿美元,并将全年收入预估从131亿美元降至84亿美元 [5] - 分析师将Iovance的评级从"增持"下调至"中性",目标价从19美元降至10美元 [5] - 2022年6月,Iovance向欧洲药品管理局提交了lifileucel用于治疗既往接受过PD-1阻断抗体治疗的无法手术切除或转移性黑色素瘤的上市申请 [6]

The Federal Reserve's fight against inflation may soon yield financial benefits.As shown by the industry-tracking SPDR S&P Biotech ETF's (XBI 0.07%) decline of 22% over the last three years, biotech stocks haven't performed well as a group in recent history. But this doesn't mean biotechs have been struggling to get their programs out of the clinic and onto the market any more than usual.There's a different phenomenon at play here. And if macroeconomic forecasts are to be believed, conditions could soon imp ...

文章核心观点 - 生物科技公司Iovance Biotherapeutics(IOVA)具有巨大的增长潜力,但要让投资者获得百倍收益并不容易 [2][3] - 即使Iovance未来20年内所有研发项目都取得成功,公司市值也很难达到能让25000美元投资变成100万美元的规模 [4][5][6][7][9][10] - 虽然Iovance的前景看好,但投资者仍需谨慎,因为生物医药行业的风险较高,竞争激烈 [11] 公司情况总结 - Iovance目前市值约24亿美元,还未盈利,2023年第一季度营收仅190万美元 [6] - 公司正在进行7个三期临床试验,另有2个一期临床试验在筹备中,主要针对各类癌症 [8] - 即使所有研发项目都成功,公司未来20年内也很难实现足够的收入和利润增长,使25000美元的投资变成100万美元 [4][5][9][10] 行业情况总结 - 生物医药行业研发成功率较低,即使针对已批准药物的适应症扩展,失败概率也很高 [10] - Iovance正考虑进入非小细胞肺癌和黑色素瘤治疗领域,这些都是竞争激烈的热门领域 [10] - 生物医药行业风险较高,投资者需谨慎考虑 [11]

First of Multiple Planned Global Submissions for Lifileucel in 2024 and 2025 Key Step in Global Expansion to Address >20,000 Patients Annually with Previously Treated Advanced Melanoma SAN CARLOS, Calif., June 28, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) cell therapies for patients with cancer, submitted a marketing authorization application ...

First of Multiple Planned Global Submissions for Lifileucel in 2024 and 2025 Key Step in Global Expansion to Address >20,000 Patients Annually with Previously Treated Advanced Melanoma SAN CARLOS, Calif., June 28, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) cell therapies for patients with cancer, submitted a marketing authorization application ( ...

The stock is down more than 50% from its 52-week high.Earlier this year, share prices of Iovance Biotherapeutics (IOVA -1.23%) were soaring after one of its therapies obtained approval from regulators. Iovance stock would go on to reach share price highs of more than $18. Today, however, the stock trades at less than half that price. And in just three months, it has fallen by more than 40% as the hype surrounding the business appears to have evaporated.Is it too late to invest in Iovance, or could the best ...

New data indicate that its cell therapy could soon find a larger market.It's always a nice surprise to see that a company you're invested in is making good on its opportunities and planning to grow on your behalf. In that vein, at the 2024 meeting of the American Society of Clinical Oncology (ASCO) on May 31, Iovance Biotherapeutics (IOVA 0.58%) offered some news that should please its shareholders and perhaps motivate them to buy more of the stock in the near term.To appreciate what it disclosed and why it ...

SAN CARLOS, Calif., May 24, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ:IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that senior leadership plans to present at the following conferences and events: TD Cowen 5th Annual Oncology Innovation Summit: Insights for ASCO & EHAFireside Chat: May 28, 2024 at 3:00 p.m. ETVirtual Iovance ASCO Investor/Analyst Ev ...

SAN CARLOS, Calif., May 24, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that senior leadership plans to present at the following conferences and events: TD Cowen 5th Annual Oncology Innovation Summit: Insights for ASCO & EHAFireside Chat: May 28, 2024 at 3:00 p.m. ETVirtual Iovance ASCO Investor/Analyst E ...